Welcome to our dedicated page for FEMASYS news (Ticker: FEMY), a resource for investors and traders seeking the latest updates and insights on FEMASYS stock.
Femasys Inc. develops biomedical products for women’s reproductive health, with news centered on fertility treatment, fallopian tube assessment, and non-surgical permanent birth control. Its portfolio includes FemaSeed intratubal insemination, FemaSeed Complete for in-office fertility care, FemVue for ultrasound-based fallopian tube evaluation, FemBloc permanent birth control, and related diagnostic products such as FemChec.
Recurring updates cover product commercialization in OB/GYN settings, international distribution and market access, regulatory approvals outside the United States, U.S. clinical and regulatory development for FemBloc, reimbursement-related developments, financing, operating results, and governance changes.
Femasys Inc. (NASDAQ: FEMY) has initiated a pivotal trial for its innovative infertility treatment, FemaSeed, which features localized directional insemination. The trial, named LOCAL, aims to enroll up to 792 patients across 20 U.S. centers to evaluate safety and effectiveness. The trial's primary endpoints are clinical pregnancy rates and safety measures over a duration of seven weeks. This initiative underscores Femasys' commitment to providing cost-effective, less invasive infertility solutions amid a growing public health concern.
On June 21, 2021, Chardan announced its role as the lead left bookrunner for the $34.45 million IPO of Femasys, Inc. (NASDAQ: FEMY), a biomedical company dedicated to women's healthcare. The funds raised will support Femasys’ clinical trials for its FemBloc and FemaSeed systems, along with product development and hiring efforts. Chardan has prioritized investing in healthcare companies addressing significant unmet needs, reflecting a commitment to ESG principles.